Lymphoma / Lymphosarcoma (LSA)

Lymphoma, also known as lymphosarcoma (LSA), is the most common cancer diagnosed in cats, accounting for approximately thirty percent of all feline malignancies. This cancer arises from lymphocytes, which are white blood cells that play a crucial role in the immune system. Lymphoma can develop virtually anywhere in the body where lymphatic tissue is present, which includes lymph nodes throughout the body, the gastrointestinal tract, chest cavity, kidneys, nasal passages, central nervous system, and skin. The widespread distribution of lymphatic tissue explains why lymphoma can present in so many different anatomical forms, each with its own characteristic clinical signs, treatment approach, and prognosis.

The development of lymphoma involves malignant transformation of lymphocytes, causing them to proliferate uncontrollably and accumulate in tissues. The specific trigger for this transformation varies. Historically, feline leukemia virus infection was responsible for a large proportion of feline lymphoma cases, but widespread testing and vaccination have reduced FeLV-associated lymphoma. Today, the majority of lymphoma cases in cats occur in FeLV-negative individuals, and the exact cause is often unknown. The gastrointestinal form, known as alimentary lymphoma, has become the most common presentation in recent decades, particularly in older cats. Research suggests that chronic intestinal inflammation may predispose to this form of lymphoma.

Lymphoma significantly impacts the health and quality of life of affected cats. The clinical effects depend on which organs are involved and the extent of disease. Alimentary lymphoma causes gastrointestinal symptoms including vomiting, diarrhea, and weight loss. Mediastinal lymphoma in the chest causes respiratory distress due to masses and fluid accumulation. Multicentric lymphoma causes widespread lymph node enlargement. Renal lymphoma affects kidney function, while nasal lymphoma causes breathing difficulty and facial changes. Regardless of location, advanced lymphoma impairs immune function and causes systemic effects including weight loss, lethargy, and poor appetite.

Despite being a serious diagnosis, lymphoma is one of the most treatable cancers in cats. Chemotherapy is the primary treatment modality and can induce remission in a significant proportion of cases. Unlike in humans, cats typically tolerate chemotherapy well, with manageable side effects that rarely affect quality of life significantly. The prognosis varies greatly depending on the anatomical form, the grade of the lymphoma, FeLV status, and response to treatment. Some cats achieve remission periods of a year or more with good quality of life, while others have more resistant disease. Veterinary oncologists work with primary care veterinarians and owners to develop individualized treatment plans that balance efficacy with quality of life considerations.

The causes of feline lymphoma vary depending on the type and have evolved over time as the feline population has changed. Historically, feline leukemia virus was the primary cause, responsible for the majority of lymphoma cases. FeLV is a retrovirus that integrates into the host cell's genome and can activate oncogenes or disrupt tumor suppressor genes, leading to malignant transformation of lymphocytes. FeLV-associated lymphomas were particularly common in young cats and often presented as mediastinal or multicentric forms. With widespread implementation of FeLV testing, segregation of positive cats, and vaccination programs, FeLV-associated lymphoma has decreased substantially in prevalence in many regions.

In the current era, most feline lymphoma cases occur in FeLV-negative cats, and the causes are less well understood. Chronic antigenic stimulation and inflammation are suspected to play a role, particularly in alimentary lymphoma. Inflammatory bowel disease has been associated with increased risk of intestinal lymphoma development, suggesting a progression from inflammation to cancer in some cases. The relationship between IBD and lymphoma is complex, as the two conditions can be difficult to distinguish and may represent different points on a spectrum of intestinal disease. Environmental factors including exposure to tobacco smoke have been investigated as potential contributors to feline lymphoma risk.

Genetic factors in feline lymphoma are not clearly defined in terms of inherited breed predisposition. However, genetic changes within the tumor cells themselves drive cancer behavior. Specific chromosomal abnormalities and gene mutations have been identified in feline lymphoma and influence the lymphoma subtype and aggressiveness. The cell of origin, whether B-lymphocyte or T-lymphocyte, affects disease behavior, with most alimentary lymphomas being of B-cell origin and many mediastinal lymphomas being T-cell derived. Research into the molecular characteristics of feline lymphoma is ongoing and may eventually lead to more targeted treatment approaches.

Risk factors for developing lymphoma include age, FeLV status, and possibly chronic gastrointestinal disease. The median age at diagnosis for alimentary lymphoma is approximately twelve years, reflecting the current predominance of this form in older cats. FeLV-positive cats, while representing a smaller proportion of cases than historically, remain at significantly elevated risk. Cats with chronic enteropathy or inflammatory bowel disease may have increased risk of alimentary lymphoma development, though causality is not definitively established. Indoor cats appear to have higher rates of alimentary lymphoma compared to outdoor cats, possibly reflecting longer lifespans that allow age-related cancers to develop.

The mechanism of lymphoma development involves sequential genetic alterations that transform normal lymphocytes into malignant cells. Early mutations may provide growth advantages, allowing affected cells to proliferate more rapidly than normal lymphocytes. Additional mutations accumulate, further deregulating cell growth and survival pathways. Eventually, the fully malignant phenotype emerges, with cells that proliferate uncontrollably, evade normal cell death mechanisms, and have the ability to invade tissues and spread throughout the body. The specific mutations and affected pathways influence the behavior of the resulting lymphoma, including its location, growth rate, and response to treatment.

Early warning signs of lymphoma in cats often begin subtly and depend on the anatomical form of the disease. For alimentary lymphoma, the most common form, early signs typically include gradual weight loss that may initially be attributed to aging. Subtle changes in appetite, such as increased pickiness or decreased food intake, often precede more obvious symptoms. Intermittent vomiting or soft stools may occur and be dismissed as hairballs or dietary indiscretion. For other lymphoma forms, early signs similarly reflect the location, with mediastinal lymphoma potentially causing subtle breathing changes and multicentric lymphoma causing barely noticeable lymph node enlargement. Because cats are masters at hiding illness, early symptoms are frequently missed or attributed to normal aging.

Common symptoms of feline lymphoma vary by anatomical location. Alimentary lymphoma causes vomiting, diarrhea or constipation, significant weight loss, decreased appetite, and sometimes abdominal discomfort. Mediastinal lymphoma causes labored breathing, open-mouth breathing, coughing, reluctance to lie down, and sometimes difficulty swallowing due to masses in the chest. Multicentric lymphoma presents with generalized lymph node enlargement, which owners may notice as swellings in the neck, behind the knees, or in the groin. Renal lymphoma may cause increased drinking and urination as kidney function is affected. Nasal lymphoma causes nasal discharge, sneezing, difficulty breathing, and sometimes facial deformity.

Behavioral changes commonly accompany the physical symptoms of lymphoma. Affected cats often become less active, sleeping more and playing less. Decreased grooming leads to a rougher, less maintained coat appearance. Changes in social behavior may occur, with some cats becoming more clingy while others withdraw and seek isolation. Appetite changes range from complete anorexia to altered food preferences. Litter box habits may change, particularly with alimentary lymphoma causing diarrhea or constipation. Vocalizations may increase, potentially indicating discomfort. Any significant behavioral change in an older cat warrants veterinary evaluation to rule out serious conditions including cancer.

Physical signs visible on examination vary by lymphoma type. Weight loss, often dramatic, is visible as prominent bones and loss of muscle mass. Palpable abdominal masses or thickened intestinal loops may be detected in alimentary lymphoma. Enlarged lymph nodes feel like firm swellings under the skin. Pale gums indicate anemia, which can occur secondary to chronic disease or bone marrow involvement. Jaundice, with yellow discoloration of the gums and whites of the eyes, suggests liver involvement. Abdominal distension may result from masses, enlarged organs, or fluid accumulation. Labored breathing may be visible with mediastinal disease. Facial asymmetry or swelling occurs with nasal lymphoma.

Symptom progression in untreated lymphoma generally follows a pattern of gradual worsening, though the pace varies by lymphoma type. Low-grade alimentary lymphoma may progress slowly over months, while high-grade forms and mediastinal lymphoma tend to progress more rapidly over weeks. Weight loss becomes more pronounced, and appetite continues to decline. Symptoms related to specific organ involvement worsen as tumor burden increases. Systemic effects including weakness, lethargy, and poor overall condition become more apparent. Secondary complications, including infections due to compromised immunity and anemia, may develop. Without treatment, the trend is toward progressive decline.

Emergency symptoms requiring immediate veterinary attention include severe respiratory distress, which is a common presentation of mediastinal lymphoma and requires urgent intervention to remove fluid from the chest cavity. Profound weakness or collapse may indicate severe anemia or other critical complications. Complete inability to eat for more than twenty-four hours can rapidly lead to hepatic lipidosis in cats. Severe vomiting or diarrhea with signs of dehydration needs urgent care. Sudden neurological changes such as seizures, blindness, or severe incoordination may indicate central nervous system involvement. Any acute deterioration should prompt emergency evaluation.

Initial examination of a cat suspected to have lymphoma includes a comprehensive physical assessment guided by the presenting symptoms. The veterinarian will palpate the entire body to detect enlarged lymph nodes, abdominal masses, thickened intestinal loops, or organ enlargement. Examination of the chest with a stethoscope may reveal muffled sounds suggesting pleural effusion or masses. Body weight, muscle condition, and hydration status are assessed. A thorough history including symptom duration, progression, and any previous health issues helps guide the diagnostic workup. Temperature is recorded, as fever can occur with lymphoma or secondary infections.

Diagnostic testing for suspected lymphoma involves multiple modalities to confirm the diagnosis and determine the extent of disease. Blood work typically includes a complete blood count, which may reveal anemia or abnormal white blood cell counts, and a chemistry panel to assess organ function. FeLV and FIV testing should be performed if status is unknown. Imaging is essential, with chest radiographs evaluating for mediastinal masses and pleural effusion, and abdominal ultrasound assessing the gastrointestinal tract, liver, spleen, kidneys, and abdominal lymph nodes. Ultrasound is particularly valuable for detecting thickened intestinal walls, enlarged lymph nodes, and masses that might not be palpable on examination.

The critical step in diagnosing lymphoma is obtaining tissue or cell samples for microscopic examination. Fine needle aspiration of enlarged lymph nodes, masses, or affected organs can often provide a rapid presumptive diagnosis through cytological examination. This minimally invasive technique is frequently diagnostic and can be performed without sedation in many cases. However, definitive diagnosis and classification, particularly for alimentary lymphoma, typically requires biopsy samples for histopathology. Gastrointestinal lymphoma is often diagnosed through endoscopic biopsies or surgical full-thickness biopsies. Immunohistochemistry determines whether the lymphoma is of B-cell or T-cell origin, and grading as low-grade or high-grade significantly impacts prognosis and treatment planning.

Differential diagnosis is important because other conditions can mimic lymphoma. Inflammatory bowel disease shares many symptoms with alimentary lymphoma and can be difficult to distinguish even with biopsy, sometimes requiring immunohistochemistry or clonality testing. Other cancers, including mast cell tumors, carcinomas, and other sarcomas, may present similarly depending on location. Infectious causes of lymph node enlargement, including fungal infections and mycobacterial disease, should be considered. Mediastinal masses in young cats may include thymoma or other tumors. Non-neoplastic causes of pleural effusion, abdominal masses, or kidney enlargement enter the differential for various lymphoma presentations. Accurate diagnosis through appropriate sampling and testing is essential for proper treatment planning.

Immediate treatment priorities for cats diagnosed with lymphoma focus on stabilization and addressing any life-threatening complications. Cats presenting with respiratory distress due to mediastinal lymphoma require thoracocentesis to remove pleural fluid and provide breathing relief. Severely dehydrated cats need intravenous fluid therapy to restore hydration before chemotherapy can safely begin. Nutritional support is initiated for cats with significant weight loss or anorexia. If severe anemia is present, blood transfusion may be necessary. Anti-nausea medications help manage vomiting in cats with alimentary lymphoma. These supportive measures prepare the cat for definitive cancer treatment.

Chemotherapy is the mainstay of treatment for most forms of feline lymphoma. The specific protocol depends on the lymphoma type, grade, and individual patient factors. Multi-agent chemotherapy using combinations of drugs such as vincristine, cyclophosphamide, doxorubicin, and prednisone is commonly used for intermediate to high-grade lymphoma. These CHOP-based protocols achieve remission in approximately fifty to seventy percent of cats, with median survival times ranging from six months to over two years depending on the specific circumstances. Low-grade alimentary lymphoma is often treated with oral chlorambucil and prednisolone, which is well tolerated and can achieve prolonged survival times, sometimes exceeding two years. Cats generally tolerate chemotherapy much better than humans, with most experiencing minimal side effects.

Surgical intervention plays a role in specific circumstances but is not the primary treatment for most lymphoma cases. For solitary intestinal masses causing obstruction, surgical removal followed by chemotherapy may be recommended. Surgical debulking of localized disease may be considered in conjunction with other treatments. Splenectomy may be appropriate when lymphoma is confined to the spleen. Full-thickness surgical biopsies are sometimes necessary for diagnosis when endoscopic biopsies are inconclusive. However, because lymphoma is generally considered a systemic disease even when it appears localized, surgery alone is rarely curative, and chemotherapy remains the primary treatment modality.

Supportive care is essential throughout treatment and significantly impacts quality of life and treatment success. Nutritional support through appetite stimulants, anti-nausea medications, and sometimes feeding tubes helps maintain body condition. Pain management is provided when indicated. Anti-nausea medications control treatment-related gastrointestinal upset. Fluid therapy maintains hydration during periods of decreased intake. Antibiotics treat secondary infections when they occur. Monitoring and management of chemotherapy side effects, though usually mild, ensures that treatment remains tolerable. Quality of life assessment guides supportive care intensity and informs treatment decisions.

Alternative and complementary approaches may be considered alongside conventional treatment. Nutritional supplements and immune-supporting products are sometimes used, though evidence for efficacy specifically in feline lymphoma is limited. Acupuncture may help manage pain, nausea, and treatment side effects. Herbal therapies should be approached cautiously due to potential interactions with chemotherapy drugs. Some owners pursue holistic approaches as adjuncts to conventional treatment or as primary therapy when chemotherapy is declined. Any complementary therapies should be discussed with the veterinary oncologist to ensure safety and avoid interference with primary treatment.

Treatment decisions in feline lymphoma require balancing multiple factors. The lymphoma type, grade, and extent influence expected response to treatment. The cat's overall health, age, and presence of concurrent diseases affect ability to tolerate treatment. FeLV status influences prognosis. Practical factors including treatment costs, which can range from hundreds to thousands of dollars, required veterinary visit frequency, and home care demands must be realistically assessed. Quality of life during treatment is paramount, and most veterinary oncologists emphasize that treatment should not compromise the cat's enjoyment of life. Some owners pursue aggressive multi-agent chemotherapy, while others opt for gentler oral protocols or palliative care. There is no single right answer, and treatment plans should reflect individual circumstances and values.

The recovery timeline for cats undergoing lymphoma treatment is measured in terms of response to chemotherapy and duration of remission rather than cure. Response assessment typically occurs after the first few treatment cycles, usually within two to four weeks of starting therapy. Complete remission, meaning no detectable cancer, is achieved in approximately fifty to seventy percent of cats with intermediate to high-grade lymphoma receiving multi-agent chemotherapy. Low-grade alimentary lymphoma treated with oral protocols often achieves excellent long-term control, with some cats remaining in remission for years. The median remission duration varies widely depending on lymphoma type, ranging from several months to over two years.

Post-treatment care during and following chemotherapy requires ongoing attention to the cat's wellbeing and monitoring for complications. Regular veterinary visits are necessary for chemotherapy administration, response assessment, and blood count monitoring. For injectable protocols, visits may be weekly initially, then less frequent as treatment continues. Oral protocols may allow for less frequent veterinary visits but still require regular monitoring. Between appointments, owners should watch for signs of chemotherapy side effects, including decreased appetite, vomiting, diarrhea, or unusual lethargy. Most cats tolerate treatment well, but significant side effects should be reported promptly. After completing treatment, periodic rechecks monitor for relapse.

Prognostic factors for feline lymphoma are numerous and significantly affect expected outcomes. The anatomical form is important, with nasal lymphoma generally having a better prognosis than most other forms, and alimentary lymphoma prognosis varying by grade. Low-grade alimentary lymphoma has a significantly better prognosis than high-grade forms. FeLV-negative cats have longer survival times than FeLV-positive cats with the same lymphoma type. Complete response to initial chemotherapy predicts better outcomes than partial response. B-cell lymphomas often respond better than T-cell forms. The presence of hypercalcemia, anemia, or advanced disease at diagnosis negatively affects prognosis.

Long-term outlook for cats with lymphoma varies widely but can be measured in quality months to years for many cats. Low-grade alimentary lymphoma treated with oral protocols can achieve median survival times exceeding two years, with some cats living much longer. High-grade lymphomas and those associated with FeLV have shorter median survival times, often in the range of six to nine months with treatment, though individual cats may do better or worse. Relapse is expected eventually in most cases, though some cats may achieve very long remissions. Rescue protocols can sometimes induce second remissions, though these are typically shorter than the initial remission. End-of-life planning, including discussions about transitioning to palliative care and euthanasia, should occur early to allow thoughtful decision-making.

Primary prevention of feline lymphoma focuses on reducing known risk factors, particularly feline leukemia virus infection. Vaccination against FeLV is recommended for at-risk cats, including those with outdoor access or those living with FeLV-positive cats or cats of unknown status. The vaccine significantly reduces, though does not eliminate, infection risk. Keeping cats indoors eliminates exposure to FeLV-positive cats and is the most effective prevention strategy. Testing cats for FeLV before introduction to households prevents inadvertent exposure. For FeLV-positive cats, preventing further viral transmission through responsible management reduces the overall burden of virus-associated lymphoma in the cat population.

Environmental prevention measures for lymphoma are less well established than for FeLV control. Reducing exposure to environmental tobacco smoke may decrease cancer risk, including possibly lymphoma, though direct evidence is limited. Minimizing exposure to potential carcinogens including certain pesticides and chemicals is prudent general advice. A clean, low-stress living environment supports immune function, which plays a role in cancer surveillance. While specific environmental modifications proven to prevent lymphoma are not established, general measures supporting feline health are reasonable and may have protective effects.

Nutritional considerations for lymphoma prevention are not established but may play a supportive role in overall cancer resistance. Feeding a balanced, high-quality diet supports immune function and overall health. For cats with inflammatory bowel disease, which may predispose to alimentary lymphoma, appropriate dietary management to control inflammation may theoretically reduce cancer risk, though this has not been proven. Maintaining healthy body weight through proper nutrition reduces obesity-associated health risks. No specific diet or supplement has been shown to prevent feline lymphoma, but optimal nutrition supports the body's defenses.

Regular health maintenance creates opportunities for early detection, which significantly impacts treatment outcomes. Annual or biannual veterinary examinations allow assessment of overall health and detection of subtle abnormalities. Weight monitoring is particularly important, as unexplained weight loss may be an early sign of alimentary lymphoma. Routine blood work, particularly for older cats, may reveal abnormalities warranting further investigation. Prompt evaluation of any health changes, rather than attributing them to normal aging, allows earlier diagnosis. For cats with inflammatory bowel disease, regular monitoring including periodic intestinal biopsies may be recommended to detect early neoplastic transformation.

Early intervention when symptoms develop offers the best opportunity for successful treatment. Any unexplained weight loss, changes in appetite, vomiting, diarrhea, or breathing difficulties should prompt veterinary evaluation. Older cats experiencing gradual decline should not be assumed to be aging normally without appropriate workup. Early-stage lymphoma, with lower tumor burden, may respond better to treatment and achieve longer remission times than advanced disease. The combination of vigilant observation, prompt veterinary consultation, and appropriate diagnostic workup gives cats the best chance for optimal outcomes.

Daily management of a cat undergoing lymphoma treatment requires consistent attention to medication, nutrition, and wellbeing monitoring. Oral medications, whether chemotherapy agents or supportive medications, must be administered as prescribed. Safe handling of chemotherapy drugs, including wearing gloves and washing hands after administration, protects both the cat and family members. Monitoring food and water intake helps assess wellbeing, with decreased appetite often being an early sign of problems. Daily observation for signs of illness or treatment side effects allows early intervention. A log of weight, appetite, and any symptoms helps track trends and communicate effectively with the veterinary team.

The home environment should be optimized to support comfort and reduce stress. Providing quiet resting areas allows undisturbed sleep and recovery from treatment. Easy access to food, water, and litter boxes is important, especially for cats with reduced energy. Keeping multiple water sources encourages hydration. Comfortable bedding and access to warm spots, such as sunny windows, supports comfort. For cats with respiratory involvement, avoiding dust, smoke, and other respiratory irritants helps. A clean, calm environment with minimal disruption to routine reduces stress that could negatively impact immune function and treatment response.

Maintaining quality of life is the central goal throughout lymphoma treatment. During remission, most cats feel well and can enjoy normal activities including play, companionship, and favorite pastimes. Adapting activities to energy level ensures enjoyment without exhaustion. Continuing positive interactions, whether gentle play, petting, or simply spending time together, maintains the human-animal bond and provides mental stimulation. Recognizing what brings joy to the individual cat and facilitating those experiences contributes to daily quality of life. Quality of life should be assessed regularly, with honest evaluation of whether the cat is enjoying life.

Ongoing monitoring and veterinary communication are essential throughout treatment and beyond. Regular rechecks allow assessment of treatment response, detection of relapse, and adjustment of protocols as needed. Blood tests monitor for treatment side effects and disease progression. Between appointments, owners should contact the veterinary team if concerning changes occur, including decreased appetite, significant lethargy, vomiting, or other symptoms. Honest discussions about quality of life help guide treatment decisions. As the disease progresses or if relapse occurs, discussions about continuing treatment, switching to palliative care, or considering euthanasia should occur proactively.

Caregiver support is an important consideration when managing a cat with cancer. The emotional demands of caring for a seriously ill pet are significant, and anticipatory grief is common. Connecting with support resources, whether veterinary social workers, pet loss support groups, or understanding friends and family, helps caregivers cope. The financial costs of lymphoma treatment can be substantial, and honest assessment of resources helps with treatment planning. Time demands for veterinary visits and home care should be realistically evaluated. Self-care for caregivers is essential for sustaining the ability to provide quality care. Planning for end of life, including preferred timing and location for euthanasia, can reduce decision-making burden during difficult times.

Feline lymphoma does not show strong breed predispositions, as the cancer can occur in any cat regardless of breed or ancestry. Domestic shorthairs and domestic longhairs account for the majority of cases, reflecting their prevalence in the general cat population rather than increased susceptibility. Some studies have suggested possible slight increases in lymphoma risk in certain breeds, including Siamese cats for mediastinal lymphoma historically associated with FeLV, but these associations are not consistently demonstrated across studies. Overall, breed is not a primary factor in lymphoma risk assessment, and prevention efforts should focus on other risk factors regardless of breed.

Demographic factors other than breed have stronger associations with lymphoma risk. Age is the most significant factor for alimentary lymphoma, which predominantly affects older cats with a median age at diagnosis of approximately twelve years. FeLV-positive cats have substantially elevated lymphoma risk compared to uninfected cats, with younger ages at diagnosis typical for virus-associated forms. Indoor cats appear to have higher rates of alimentary lymphoma, possibly reflecting longer lifespans. Cats with chronic inflammatory bowel disease may be at increased risk for alimentary lymphoma development. These factors provide more meaningful risk information than breed.

For all cats, regardless of breed, prevention and early detection approaches are similar. FeLV testing at adoption and vaccination of at-risk cats reduces virus-associated lymphoma risk. Keeping cats indoors protects against FeLV exposure. Regular veterinary examinations with attention to weight changes and gastrointestinal symptoms allow early detection. Prompt evaluation of unexplained weight loss, appetite changes, or gastrointestinal symptoms is important in all cats but especially older cats at higher risk for alimentary lymphoma. These recommendations apply across all breeds and ancestry types.

Several conditions commonly co-occur with feline lymphoma or share associations with it. Inflammatory bowel disease is closely related to alimentary lymphoma, with debate about whether they represent a continuum of intestinal disease. Distinguishing between IBD and low-grade lymphoma can be challenging, sometimes requiring advanced diagnostic techniques. Feline leukemia virus infection predisposes to lymphoma and may be concurrent with the cancer. Other FeLV-associated conditions, including anemia, immunosuppression, and other cancers, may coexist with lymphoma in FeLV-positive cats. Chronic kidney disease may be present in older cats who develop lymphoma and requires concurrent management.

Other cancers and conditions may be confused with lymphoma due to similar presentations. Intestinal adenocarcinoma can present similarly to alimentary lymphoma with gastrointestinal symptoms and intestinal masses. Mast cell tumors can occur in the intestines and must be distinguished from lymphoma. Inflammatory conditions causing lymph node enlargement, including infections and reactive hyperplasia, may mimic multicentric lymphoma. Thymoma and other mediastinal masses can present similarly to mediastinal lymphoma. Non-neoplastic causes of abdominal masses, kidney enlargement, or nasal disease enter the differential for various lymphoma presentations. Accurate diagnosis through appropriate sampling and testing guides proper treatment.

Complications of lymphoma and its treatment require monitoring and management. Tumor lysis syndrome, though less common in cats than in some species, can occur when chemotherapy rapidly destroys large numbers of cancer cells. Chemotherapy side effects, while usually mild in cats, may include myelosuppression with decreased blood cell counts, gastrointestinal upset, and rarely more severe toxicities. Secondary infections can occur due to immunosuppression from both the cancer and treatment. Relapse after initial remission is expected in most cases of high-grade lymphoma. Paraneoplastic syndromes, including hypercalcemia, can occur with certain lymphoma types. Close monitoring and proactive management of complications help maintain quality of life throughout the disease course.